Satsuma Pharmaceuticals Competitors

Satsuma Pharmaceuticals (NASDAQ:STSA) and Truist Financial (NYSE:TFC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Profitability

This table compares Satsuma Pharmaceuticals and Truist Financial's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Satsuma Pharmaceuticals and Truist Financial's gross revenue, earnings per share and valuation.

Truist Financial has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than Truist Financial, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.1% of Satsuma Pharmaceuticals shares are owned by institutional investors. Comparatively, 73.4% of Truist Financial shares are owned by institutional investors. 45.7% of Satsuma Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Truist Financial shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Satsuma Pharmaceuticals and Truist Financial, as provided by MarketBeat.

Satsuma Pharmaceuticals currently has a consensus target price of $4.6250, indicating a potential downside of 1.18%. Truist Financial has a consensus target price of $45.0789, indicating a potential downside of 6.96%. Given Satsuma Pharmaceuticals' higher possible upside, research analysts clearly believe Satsuma Pharmaceuticals is more favorable than Truist Financial.

Summary

Truist Financial beats Satsuma Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Satsuma Pharmaceuticals (NASDAQ:STSA) and The PNC Financial Services Group (NYSE:PNC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Profitability

This table compares Satsuma Pharmaceuticals and The PNC Financial Services Group's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Satsuma Pharmaceuticals and The PNC Financial Services Group, as reported by MarketBeat.

Satsuma Pharmaceuticals currently has a consensus target price of $4.6250, indicating a potential downside of 1.18%. The PNC Financial Services Group has a consensus target price of $128.40, indicating a potential downside of 8.16%. Given Satsuma Pharmaceuticals' higher probable upside, equities research analysts clearly believe Satsuma Pharmaceuticals is more favorable than The PNC Financial Services Group.

Institutional and Insider Ownership

79.1% of Satsuma Pharmaceuticals shares are held by institutional investors. Comparatively, 79.5% of The PNC Financial Services Group shares are held by institutional investors. 45.7% of Satsuma Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of The PNC Financial Services Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Satsuma Pharmaceuticals and The PNC Financial Services Group's top-line revenue, earnings per share and valuation.

The PNC Financial Services Group has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than The PNC Financial Services Group, indicating that it is currently the more affordable of the two stocks.

Summary

The PNC Financial Services Group beats Satsuma Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

First Republic Bank (NYSE:FRC) and Satsuma Pharmaceuticals (NASDAQ:STSA) are both finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for First Republic Bank and Satsuma Pharmaceuticals, as reported by MarketBeat.

First Republic Bank presently has a consensus price target of $123.3750, suggesting a potential downside of 5.45%. Satsuma Pharmaceuticals has a consensus price target of $4.6250, suggesting a potential downside of 1.18%. Given Satsuma Pharmaceuticals' higher possible upside, analysts plainly believe Satsuma Pharmaceuticals is more favorable than First Republic Bank.

Valuation and Earnings

This table compares First Republic Bank and Satsuma Pharmaceuticals' gross revenue, earnings per share and valuation.

First Republic Bank has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than First Republic Bank, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares First Republic Bank and Satsuma Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

95.7% of First Republic Bank shares are owned by institutional investors. Comparatively, 79.1% of Satsuma Pharmaceuticals shares are owned by institutional investors. 45.7% of Satsuma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

First Republic Bank beats Satsuma Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

Satsuma Pharmaceuticals (NASDAQ:STSA) and Fifth Third Bancorp (NASDAQ:FITB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Earnings and Valuation

This table compares Satsuma Pharmaceuticals and Fifth Third Bancorp's revenue, earnings per share and valuation.

Fifth Third Bancorp has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than Fifth Third Bancorp, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Satsuma Pharmaceuticals and Fifth Third Bancorp, as reported by MarketBeat.com.

Satsuma Pharmaceuticals currently has a consensus target price of $4.6250, indicating a potential downside of 1.18%. Fifth Third Bancorp has a consensus target price of $23.85, indicating a potential downside of 9.14%. Given Satsuma Pharmaceuticals' higher possible upside, analysts clearly believe Satsuma Pharmaceuticals is more favorable than Fifth Third Bancorp.

Profitability

This table compares Satsuma Pharmaceuticals and Fifth Third Bancorp's net margins, return on equity and return on assets.

Institutional and Insider Ownership

79.1% of Satsuma Pharmaceuticals shares are held by institutional investors. Comparatively, 78.5% of Fifth Third Bancorp shares are held by institutional investors. 45.7% of Satsuma Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Fifth Third Bancorp shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Fifth Third Bancorp beats Satsuma Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Satsuma Pharmaceuticals (NASDAQ:STSA) and SVB Financial Group (NASDAQ:SIVB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Satsuma Pharmaceuticals and SVB Financial Group's top-line revenue, earnings per share (EPS) and valuation.

SVB Financial Group has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than SVB Financial Group, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Satsuma Pharmaceuticals and SVB Financial Group, as provided by MarketBeat.com.

Satsuma Pharmaceuticals currently has a consensus price target of $4.6250, indicating a potential downside of 1.18%. SVB Financial Group has a consensus price target of $257.7333, indicating a potential downside of 27.15%. Given Satsuma Pharmaceuticals' higher probable upside, equities research analysts plainly believe Satsuma Pharmaceuticals is more favorable than SVB Financial Group.

Profitability

This table compares Satsuma Pharmaceuticals and SVB Financial Group's net margins, return on equity and return on assets.

Institutional and Insider Ownership

79.1% of Satsuma Pharmaceuticals shares are held by institutional investors. Comparatively, 90.0% of SVB Financial Group shares are held by institutional investors. 45.7% of Satsuma Pharmaceuticals shares are held by insiders. Comparatively, 0.8% of SVB Financial Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

SVB Financial Group beats Satsuma Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

KeyCorp (NYSE:KEY) and Satsuma Pharmaceuticals (NASDAQ:STSA) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares KeyCorp and Satsuma Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for KeyCorp and Satsuma Pharmaceuticals, as provided by MarketBeat.com.

KeyCorp presently has a consensus price target of $18.2833, indicating a potential upside of 11.96%. Satsuma Pharmaceuticals has a consensus price target of $4.6250, indicating a potential downside of 1.18%. Given KeyCorp's higher probable upside, analysts plainly believe KeyCorp is more favorable than Satsuma Pharmaceuticals.

Institutional & Insider Ownership

79.7% of KeyCorp shares are owned by institutional investors. Comparatively, 79.1% of Satsuma Pharmaceuticals shares are owned by institutional investors. 0.7% of KeyCorp shares are owned by insiders. Comparatively, 45.7% of Satsuma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares KeyCorp and Satsuma Pharmaceuticals' top-line revenue, earnings per share and valuation.

KeyCorp has higher revenue and earnings than Satsuma Pharmaceuticals. Satsuma Pharmaceuticals is trading at a lower price-to-earnings ratio than KeyCorp, indicating that it is currently the more affordable of the two stocks.

Summary

KeyCorp beats Satsuma Pharmaceuticals on 10 of the 11 factors compared between the two stocks.